58707-34-9

Upstream product

• 6022-96-4 5-O-benzoyl-α-D-xylofuranose 
• 74-88-4 methyl iodide 
• 98-88-4 benzoyl chloride 
• 350255-13-9 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 18968-50-8 3'-O-methyl-1,2-O-isopropylidene-α-D-glucofuranose 
• 18968-51-9 1,2-O-isopropylidene-3-O-methyl-α-D-xylo-pentodialdo-1,4-furanose 
• 35506-61-7 ((3aR,5R,6S,6aR)-6-Methoxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-methanol 

Downstream Products

• 35506-61-7 ((3aR,5R,6S,6aR)-6-Methoxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-methanol 

Relevant academic research and scientific papers

MODIFIED RNAI AGENTS

One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more xylo modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase α

Type 2 diabetes mellitus has reached epidemic proportions; therefore, the search for novel antihyperglycemic drugs is intense. We have discovered that D-xylose increases the rate of glucose transport in a non-insulin-dependent manner in rat and human myot